Filtered By:
Condition: Bleeding
Nutrition: Vitamins
This page shows you your search results in order of date. This is page number 20.
Order by Relevance | Date
Total 1348 results found since Jan 2013.
Dabigatran versus vitamin K antagonists for atrial fibrillation in clinical practice: final outcomes from Phase III of the GLORIA-AF registry
ConclusionsDabigatran was associated with a 39% reduced risk of major bleeding and 22% reduced risk for all-cause death compared with VKA. Stroke and myocardial infarction risks were similar, confirming a more favorable benefit-risk profile for dabigatran compared with VKA in clinical practice.Clinical trial registrationhttps://www.clinicaltrials.gov. NCT01468701, NCT01671007.Graphical abstract
Source: Clinical Research in Cardiology - March 16, 2022 Category: Cardiology Source Type: research
Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry
ConclusionsPatients treated with dabigatran had a 41% lower risk of major bleeding compared with rivaroxaban, but similar risks of stroke, MI, and death. Relative to apixaban, patients treated with dabigatran had similar risks of stroke, major bleeding, MI, and death. Rivaroxaban relative to apixaban had increased risk for major bleeding, but similar risks for stroke, MI, and death.RegistrationURL:https://www.clinicaltrials.gov. Unique identifiers: NCT01468701, NCT01671007. Date of registration: September 2013.Graphical abstract
Source: Clinical Research in Cardiology - March 16, 2022 Category: Cardiology Source Type: research
Dabigatran versus vitamin K antagonists for atrial fibrillation in clinical practice: final outcomes from Phase III of the GLORIA-AF registry
ConclusionsDabigatran was associated with a 39% reduced risk of major bleeding and 22% reduced risk for all-cause death compared with VKA. Stroke and myocardial infarction risks were similar, confirming a more favorable benefit-risk profile for dabigatran compared with VKA in clinical practice.Clinical trial registrationhttps://www.clinicaltrials.gov. NCT01468701, NCT01671007.Graphical abstract
Source: Clinical Research in Cardiology - March 16, 2022 Category: Cardiology Source Type: research
Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry
ConclusionsPatients treated with dabigatran had a 41% lower risk of major bleeding compared with rivaroxaban, but similar risks of stroke, MI, and death. Relative to apixaban, patients treated with dabigatran had similar risks of stroke, major bleeding, MI, and death. Rivaroxaban relative to apixaban had increased risk for major bleeding, but similar risks for stroke, MI, and death.RegistrationURL:https://www.clinicaltrials.gov. Unique identifiers: NCT01468701, NCT01671007. Date of registration: September 2013.Graphical abstract
Source: Clinical Research in Cardiology - March 16, 2022 Category: Cardiology Source Type: research
Time in therapeutic range of anticoagulation among patients with atrial fibrillation and cerebral amyloid angiopathy
Proc (Bayl Univ Med Cent). 2021 Dec 28;35(2):162-167. doi: 10.1080/08998280.2021.2013393. eCollection 2022.ABSTRACTAtrial fibrillation (AF) and cerebral amyloid angiopathy (CAA) present risks of ischemic stroke and intracerebral hemorrhage (ICH). Vitamin K antagonist use is associated with fluctuations in international normalized ratio (INR), which predispose to a higher bleeding risk. Patients with a diagnosis of AF and ICH while on a vitamin K antagonist were identified using the Rochester Epidemiology Project. Sixty patients were identified (mean age 81.3 years; 24 men). Thirty-three (55%) exhibited characteristics cons...
Source: Baylor University Medical Center Proceedings - March 9, 2022 Category: Universities & Medical Training Authors: Robert C Ward Jonathan Graff-Radford Shiva Ponamgi Stephen English Alayna Meskill Apurva B Challa David O Hodge Joshua P Slusser Alejandro A Rabinstein Samuel J Asirvatham David Holmes Christopher V DeSimone Source Type: research
